Effect of duloxetine on tolterodine pharmacokinetics in healthy volunteers.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY(2004)
摘要
Aim To investigate the effect of duloxetine on the pharmacokinetics and tolerability of tolterodine and its active 5-hydroxymethyl metabolite (5-HM). Methods Sixteen healthy subjects received two 5-day treatment regimens in a randomized, double-blinded, crossover fashion: tolterodine (2 mg, BID) +duloxetine (40 mg, BID), tolterodine (2 mg, BID) +duloxetine placebo (BID). Plasma concentrations of tolterodine and 5-HM were measured on day 5. Adverse events, clinical safety laboratory data and vital signs were assessed during the study. Results Duloxetine increased the AUC(tau,ss) of tolterodine by 71% [geometric mean, 95% confidence interval (CI) 31, 123], and its C-max,C-ss by 64% (CI 30, 106), and prolonged its t(1/2) by 14% (CI 1, 28). Duloxetine did not affect the plasma concentrations or t(1/2) 2 of 5-HM. Laboratory data and vital signs did not reveal any clinically significant changes or abnormalities. Conclusions Duloxetine exhibited minor inhibitory effects on the pharmacokinetics of tolterodine but not 5-HM. Coadministration of these drugs was well tolerated and demonstrated no significant safety findings in the studied population. These findings suggest that there should not be a need for routine adjustment of tolterodine dosage in the presence of duloxetine.
更多查看译文
关键词
CYP2D6,duloxetine,pharmacokinetics,tolterodine
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要